文献速递肝病

终末期肝病-钠模型低估慢加急性肝衰竭患者的90天死亡风险

Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure.
PubMed 文献 · J Hepatol · 2020-06-10

该研究基于2004年1月1日至2014年12月31日127家VA医院因肝硬化住院的患者,比较慢加急性肝衰竭(ACLF)患者实际90天死亡率与基于MELD-Na计算的预期死亡率,发现ACLF患者SMR为1.52(95% CI 1.48-1.52),仅9.1%达到全国中位MELD-Na 35,表明MELD-Na低估ACLF死亡风险。

要点

  • ACLF患者90天死亡率为40.0%,无ACLF患者为21.3%。
  • ACLF总体SMR为1.52(95% CI 1.48-1.52),ACLF-1、2、3分别为1.46、1.50、1.66。
  • 仅9.1%的ACLF患者MELD-Na达到35,17.3%至35.1%超过各移植中心中位MELD-Na。

核心结论

  • 在美国因失代偿期肝硬化住院的患者队列中,MELD-Na未能反映ACLF患者的90天死亡风险,ACLF患者在现行基于MELD-Na的系统中处于不利地位。

研究设计与样本

  • 研究识别2004年1月1日至2014年12月31日期间在127家VA医院因肝硬化住院的ACLF患者,按ACLF有无及分级检查MELD-Na评分,用实际与预期90天死亡率估计标准化死亡比(SMR)。

主要发现

  • 71894例因失代偿期肝硬化住院患者中,18979例(26.4%)入院时符合ACLF标准。
  • 入院时中位(P25-P75)MELD-Na在ACLF患者为26(22-30),无ACLF患者为15(12-20);ACLF-1、2、3分别为24(21-27)、27(23-31)、32(26-37)。
  • 90天时ACLF患者死亡率为40.0%(ACLF-1、2、3分别为30.8%、41.6%、68.8%),无ACLF患者为21.3%。
  • 与基于MELD-Na的预期死亡率相比,ACLF患者死亡风险更高,总体ACLF、ACLF-1、-2、-3的SMR(95% CI)分别为1.52(1.48-1.52)、1.46(1.41-1.51)、1.50(1.44-1.55)、1.66(1.58-1.74)。
  • 仅9.1%的ACLF患者达到全国中位MELD-Na 35,17.3%至35.1%超过任何中心移植时中位MELD-Na;住院期间589例(0.8%)ACLF患者考虑肝移植评估,16例(0.1%)被列入肝移植名单。

临床怎么用

  • 作者指出,医生需要尽早启动肝移植评估,而不是等待MELD-Na数值升高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: It is unclear whether the model for end-stage liver disease-sodium (MELD-Na) score captures the clinical severity of acute-on-chronic liver failure (ACLF). We compared observed 90-day mortality in patients with ACLF with expected mortality based on the calculated MELD-Na and examined the consequences of underestimating clinical severity. METHODS: We identified patients with ACLF during hospitalization for cirrhosis in 127 VA hospitals between 01/01/2004 and 12/31/2014. We examined MELD-Na scores by ACLF presence and grade. We used actual and observed 90-day mortality to estimate a standardized mortality ratio (SMR) by ACLF presence and grade. We used transplant center-specific median MELD-Na at transplantation (MMaT) to estimate the proportion likely to receive priority for liver transplantation (LT) based on MELD-Na alone. RESULTS: Of 71,894 patients hospitalized for decompensated cirrhosis, 18,979 (26.4%) patients met the criteria for ACLF on admission. The median (P25-P75) MELD-Na on admission was 26 (22-30) for ACLF compared to 15 (12-20) for patients without ACLF; it was 24 (21-27), 27 (23-31), and 32 (26-37) for ACLF-1, 2 and 3, respectively. At 90 days, 40.0% of patients with ACLF died (30.8%, 41.6% and 68.8% with ACLF-1, 2 and 3, respectively) compared to 21.3% of patients without ACLF. Compared to the expected death rate based on MELD-Na, mortality risk was higher for patients with ACLF, SMR (95% CI): 1.52 (1.48-1.52), 1.46 (1.41-1.51), 1.50 (1.44-1.55), 1.66 (1.58-1.74) for overall ACLF, ACLF-1, -2 and -3, respectively. Only 9.1% of patients with ACLF reached the national median MELD-Na of 35 and between 17.3% to 35.1% exceeded the MMaT at any center. During index admission, 589 (0.8%) patients with ACLF were considered for LT evaluation and 16 (0.1%) were listed for LT. CONCLUSIONS: In a US cohort of hospitalized patients with decompensated cirrhosis, MELD-Na did not capture 90-day mortality risk in patients with ACLF. Patients with ACLF are at a disadvantage in the current MELD-Na-based system. LAY SUMMARY: Acute-on-chronic liver failure (ACLF) is a condition marked by multiple organ failures in patients with cirrhosis and is associated with a high risk of death. Liver transplantation may be the only curative treatment for these patients. A score called model for end-stage liver disease-sodium (MELD-Na) helps guide donor liver allocation for transplantation in the United States. The higher the MELD-Na score in a patient, the more likely that a patient receives a liver transplant. Our study data showed that MELD-Na score underestimates the risk of dying at 90 days in patients with ACLF. Thus, physicians need to start liver transplant evaluation early instead of waiting for a high MELD-Na number.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Hernaez R, Liu Y, Kramer JR, et al. Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure. J Hepatol. 2020. PMID: 32531416. doi:10.1016/j.jhep.2020.06.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。